121 results
-
List item
Human medicine European public assessment report (EPAR): Samsca
Tolvaptan, Inappropriate ADH Syndrome
Date of authorisation: 02/08/2009, Revision: 15, Authorised, Last updated: 01/07/2022antidiuretic hormone secretion’ (SIADH). In SIADH, an excessive amount of the … Samsca work? People with SIADH have an excessive amount … with low levels caused by SIADH and other conditions such … -
List item
Press release: Jinarc recommended for approval in rare kidney disease
Last updated: 27/02/2015antidiuretic hormone secretion (SIADH). The marketing authorisation … antidiuretic hormone secretion (SIADH). The marketing authorisation … -
List item
National expert: Consuelo Pedrós, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 79.81 KB | PDF
- Curriculum Vitae - 22.98 KB | PDF
Bolos JM. Hiponatremia y SIADH por medicamentos. Rev Esp … Garcia N. Hiponatremia y SIADH por inhibidores selectivos … -
List item
National expert: Luisa Arreaza Lopez, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 20.24 KB | PDF
Vazquez JA. Interruption of siaD in a meningococcal carrier isolate … -
List item
National expert: Paolo Pasquali, Ministry Of Health (updated)
- Declaration of interests - 79.96 KB | PDF
- Curriculum Vitae - 32.17 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Jinarc
Tolvaptan, Polycystic Kidney, Autosomal Dominant
Date of authorisation: 27/05/2015,
, Revision: 20, Authorised, Last updated: 21/10/2022
-
List item
Human medicine European public assessment report (EPAR): Javlor
vinflunine, Carcinoma, Transitional Cell; Urologic Neoplasms
Date of authorisation: 21/09/2009, Revision: 10, Authorised, Last updated: 23/11/2022 -
List item
Human medicine European public assessment report (EPAR): Duloxetine Zentiva
duloxetine, Neuralgia; Depressive Disorder, Major; Anxiety Disorders; Diabetes Mellitus
Date of authorisation: 20/08/2015,
, Revision: 11, Authorised, Last updated: 16/08/2022
-
List item
Human medicine European public assessment report (EPAR): Brintellix (updated)
Vortioxetine, Depressive Disorder, Major
Date of authorisation: 18/12/2013, Revision: 21, Authorised, Last updated: 01/03/2023 -
List item
Human medicine European public assessment report (EPAR): Quinsair
levofloxacin, Cystic Fibrosis; Respiratory Tract Infections
Date of authorisation: 25/03/2015,, Revision: 15, Authorised, Last updated: 22/12/2022
-
List item
Human medicine European public assessment report (EPAR): Thymanax
Agomelatine, Depressive Disorder, Major
Date of authorisation: 19/02/2009,
Date of refusal: 18/11/2006, Revision: 24, Authorised, Last updated: 08/08/2022 -
List item
Human medicine European public assessment report (EPAR): Valdoxan
Agomelatine, Depressive Disorder, Major
Date of authorisation: 19/02/2009, Revision: 24, Authorised, Last updated: 08/08/2022 -
List item
Human medicine European public assessment report (EPAR): Duloxetine Mylan
duloxetine, Neuralgia; Diabetic Neuropathies; Depressive Disorder, Major; Anxiety Disorders
Date of authorisation: 19/06/2015,, Revision: 17, Authorised, Last updated: 25/04/2022
-
List item
Human medicine European public assessment report (EPAR): Sifrol
pramipexole dihydrochloride monohydrate, Restless Legs Syndrome; Parkinson Disease
Date of authorisation: 13/10/1997, Revision: 36, Authorised, Last updated: 12/08/2022 -
List item
Human medicine European public assessment report (EPAR): Mirapexin
pramipexole dihydrochloride monohydrate, Restless Legs Syndrome; Parkinson Disease
Date of authorisation: 23/02/1998, Revision: 39, Authorised, Last updated: 12/08/2022 -
List item
Human medicine European public assessment report (EPAR): Duloxetine Lilly
duloxetine, Neuralgia; Diabetic Neuropathies; Depressive Disorder, Major
Date of authorisation: 08/12/2014, Revision: 9, Authorised, Last updated: 21/12/2021 -
List item
Human medicine European public assessment report (EPAR): Olanzapine Glenmark Europe
olanzapine, Schizophrenia; Bipolar Disorder
Date of authorisation: 03/12/2009,, Revision: 14, Authorised, Last updated: 20/12/2022
-
List item
Human medicine European public assessment report (EPAR): Oprymea
pramipexole dihydrochloride monohydrate, Parkinson Disease
Date of authorisation: 12/09/2008,, Revision: 22, Authorised, Last updated: 17/01/2023
-
List item
Human medicine European public assessment report (EPAR): Paxlovid (updated)
nirmatrelvir, ritonavir, COVID-19 virus infection
Date of authorisation: 28/01/2022, Revision: 10, Authorised, Last updated: 07/03/2023 -
List item
Human medicine European public assessment report (EPAR): Ranexa (previously Latixa)
ranolazine, Angina Pectoris
Date of authorisation: 08/07/2008, Revision: 22, Authorised, Last updated: 11/08/2022 -
List item
Human medicine European public assessment report (EPAR): Yentreve
duloxetine hydrochloride, Urinary Incontinence, Stress
Date of authorisation: 11/08/2004, Revision: 28, Authorised, Last updated: 21/12/2021 -
List item
Human medicine European public assessment report (EPAR): Triumeq
dolutegravir sodium, lamivudine, abacavir (as sulfate), HIV Infections
Date of authorisation: 31/08/2014, Revision: 30, Authorised, Last updated: 08/11/2022 -
List item
Human medicine European public assessment report (EPAR): Olanzapine Glenmark
olanzapine, Schizophrenia; Bipolar Disorder
Date of authorisation: 03/12/2009,, Revision: 15, Authorised, Last updated: 20/12/2022
-
List item
Human medicine European public assessment report (EPAR): Nexpovio
Selinexor, Multiple Myeloma
Date of authorisation: 26/03/2021,, Revision: 7, Authorised, Last updated: 20/02/2023
-
List item
Human medicine European public assessment report (EPAR): Cymbalta
duloxetine, Anxiety Disorders; Diabetic Neuropathies; Depressive Disorder, Major
Date of authorisation: 17/12/2004, Revision: 31, Authorised, Last updated: 21/12/2021